Systemic therapy for advanced prostate cancer

Book Section

Over fifty years after it was first used, androgen deprivation therapy (ADT) is still the mainstay for first line treatment. Unfortunately, the response to ADT is usually limited as the cancer develops an increasing profile of castrate resistant cells. Appropriate treatment recommendations throughout the course of a patient's prostate cancer are directed by the goals and desires of the patient, results of randomized clinical trials, performance status, and comorbid conditions. This chapter will discuss the systemic treatment options available to the patient with advanced prostate cancer including hormonal maneuvers, chemotherapy, bisphosphonates, systemic radiation therapy, and immunotherapy.This chapter will review the current systemic therapies for patients with castrate and non-castrate prostate cancer. © 2013 by Nova Science Publishers, Inc. All rights reserved.

Duke Authors

Cited Authors

  • Hoimes, C; Gibney, G; Kelly, WK

Published Date

  • December 1, 2012

Book Title

  • Essentials and Updates in Urologic Oncology (2 Volume Set)

Start / End Page

  • 155 - 192

International Standard Book Number 13 (ISBN-13)

  • 9781620816493

Citation Source

  • Scopus